Actualités

The retirement plan looked straightforward until March 2026. A 64-year-old couple in Pennsylvania had built a $2.4 million portfolio around a familiar target: roughly $96,000 a year in retirement spending supported by the classic 4% withdrawal framework. Then a new possibility entered the picture. The husband’s 88-year-old father, recently widowed and living alone in Florida, ... What Retirement Really Looks Like at 64 With $2.4 Million and a Father Moving Into the Guest Room Next Year

After 22 years, a couple sold their restaurant and suddenly found themselves staring at a very different balance sheet. The sale dropped $1.1 million in cash onto the table, adding to the $480,000 already sitting in a SEP-IRA. On paper, that looks like roughly $1.58 million in investable assets before taxes enter the chat like ... If You Have $480,000 Saved at 67 and Just Sold a Restaurant for $1.1 Million Cash, Here Is the Income Plan That Actually Holds

ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.

The intrinsic value estimate for Johnson & Johnson has shifted slightly, with the fair value moving from US$252.42 to US$252.96 per share, a change of about 0.2%. That subtle move lines up with recent analyst research that focuses on execution around drugs like Icotyde, Inlexzo, Tecvayli and Tremfya, as well as on how the pipeline and broader healthcare positioning are shaping sentiment. As you read on, you will see how these price target tweaks fit into the wider story and what to watch as...

CoreWeave, Inc. (NASDAQ:CRWV) was among the stocks on Jim Cramer’s radar as he highlighted the importance of lower interest rates in sustaining the broader market rally. Answering a caller’s query about the stock during the episode, Cramer said: Okay, now, I gotta tell you… CoreWeave is what I call a stock that’s not for the […]

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Johnson & Johnson's CAPLYTA (lumateperone) showed superior efficacy and favorable safety in major depressive disorder in a new network meta-analysis. The study compared CAPLYTA to other FDA approved antipsychotics used as adjunctive treatment for major depressive disorder. Results were presented at a major neuroscience meeting, highlighting comparative effectiveness and tolerability versus competing therapies. For investors tracking NYSE:JNJ, this update on CAPLYTA arrives with the stock at...

I’ve been studying portfolio concentration for years, and one stat from Schwab’s On Investing podcast keeps echoing in my head. In 2022, the Magnificent Seven fell roughly 40% while the S&P 500 dropped 18%. Our data confirms the pain: SPY shed 20% that calendar year, while Meta Platforms (NASDAQ:META) collapsed 64%, NVIDIA (NASDAQ:NVDA) fell 51%, ... The Magnificent Seven Fell 40% While the S&P Dropped 18%: Here’s How Much Tech Concentration You Can Actually Afford

Isomorphic previously raised $600 million in external funding last year, which was also led by NYC’s Thrive Capital.

Investing.com -- Analysts at Leerink Partners upgraded Johnson & Johnson from “Market Perform” to “Outperform,” citing accelerating growth prospects driven by a wave of new drug launches and expanding oncology and immunology franchises. The brokerage also raised its 12-month price target to $265 from $252, implying roughly 18% upside from the stock’s recent close.

AMD, Under Armour downgraded: Wall Street's top analyst calls

The SPDR Russell 1000 Yield Focus ETF (NYSEARCA:ONEY) harvests income from large-cap American stocks by screening the Russell 1000 for companies combining high yield with quality and low financial risk. With ONEY trading near $125 and up about 20% over the past year, the question for holders is whether the distributions backing that performance are ... Russell 1000 Dividend ETF Hits $125 as Johnson & Johnson Leads The Safety Test

S&P Global rates only two U.S. public companies AAA, one notch above the federal government itself. S&P downgraded the United States to AA+ in 2011, and Fitch followed in 2023, leaving Uncle Sam a step below the small club still graded at the top of the scale. That club has two members: Johnson & Johnson ... The 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement Portfolio

Pre-Market Stock Futures: Futures are trading mixed on Wednesday, after a rough day for technology stocks and the Nasdaq. The combination of the prospect of a longer struggle with Iran, and higher inflation, which soared to 3.8% annually, the highest since May 2023, while the core number, which is less food and energy, rose to ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap

The latest generation of the coronary intravascular lithotripsy device is designed to be more flexible to help physicians navigate tight arteries to break up calcified deposits and restore blood flow.

Johnson & Johnson (NYSE:JNJ) has launched the Shockwave C2 Aero Coronary IVL Catheter for calcified coronary artery disease, adding to its intravascular lithotripsy portfolio. The company reported key clinical results for TREMFYA in perianal fistulizing Crohn’s disease, the first major trial in this setting in roughly 20 years. JNJ-4804 produced positive data in highly refractory inflammatory bowel disease patients, pointing to potential options in difficult to treat cases. The OTTAVA...

US stocks (^DJI, ^IXIC, ^GSPC) are mixed ahead of Tuesday's market close as the Nasdaq Composite drops by over 1%, pushed lower by declines in chip stocks. Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the market reaction to the April Consumer Price Index (CPI) report released this morning.

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.

HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.

BAYRY beats Q1 earnings estimates as Crop Science sales rise, while Nubeqa and Kerendia gains help offset declines in Xarelto and Eylea.

JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) and JPMorgan Nasdaq Equity Premium Income ETF (NYSEARCA:JEPQ) pull from very different stock universes. JEPI leans on S&P 500 names with a covered call overlay. JEPQ runs the same income playbook on the Nasdaq-100. The latest fact sheets show why that distinction matters in 2026. Defensive Blue Chips Anchor ... Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields

Recent performance snapshot for Johnson & Johnson (JNJ) Johnson & Johnson (JNJ) has held relatively steady in the very short term, with the stock roughly flat over the past day but down about 1% over the past week and 7% over the past month. Over the past 3 months the share price is also down about 7%, even as the stock shows a total return of about 48% over the past year and around 50% across the past 3 and 5 years. See our latest analysis for Johnson & Johnson. The recent 7% decline in the...

We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Johnson & Johnson is among the best cancer stocks. TheFly reported on May 5 that JNJ released Phase 3 FUZION study results evaluating TREMFYA in adults with active perianal fistulizing Crohn’s disease. At 24 weeks, the therapy showed […]

Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.

The Goldman Sachs Retirement Survey 2025 captures a tension that runs through the entire retirement landscape. A full 68% of working respondents say they are confident they will meet their retirement goals. At the same time, 58% believe they will outlive their savings. Goldman calls this the Optimism Gap, a split between how workers feel ... Goldman Sachs Retirement Survey 2025: 58% of Americans Expect to Outlive Their Savings, and the Income Strategy That Changes the Math

The Goldman Sachs Retirement Survey & Insights Report 2025 puts a hard number on what many workers already sense: the bar for retirement keeps moving higher. The estimated total cost of retirement for a unisex retiree is projected to reach $2,569,000 by 2043, up from $1,747,000 in 2033. That climb reflects two forces working together. ... Goldman Sachs Retirement Survey 2025: Retirement Could Cost $2.5 Million by 2043, and Most Americans Are Not Saving Fast Enough to Keep Up

Markets are on the rise, but worries about a recession remain elevated as May gets underway.

A full-time federal minimum wage worker in the United States earns $7.25 an hour, or about $15,080 a year before taxes, working 40 hours a week for 52 weeks. The question for anyone with capital: what does it take to clear that bar without having to ask anyone, “Do you want fries with that?” On ... A $500,000 Dividend Portfolio That Pays More Than a Full-Time Minimum Wage Job

From AI-accelerated drug discovery to a $55 billion domestic manufacturing push, the U.S. health innovation engine is just getting started.

A new Nationwide Retirement Institute survey paints a stark picture: most Americans approaching retirement do not actually understand the program they are banking on. Only 21% of respondents correctly identified their full retirement age based on their year of birth, and the average adult answered just 8 of 15 true-or-false questions about Social Security correctly. ... The Nationwide Social Security Survey Says Most Americans Are Flying Blind on Benefits, Here’s the Income Strategy That Fills t